These formulations are particularly preferred for chronic management of obesity, as they ensure higher bioavailability compared to oral alternatives and allow the use of long-acting, once-weekly or once-daily therapies
This month, the FDA approved empagliflozin (Jardiance) to reduce the risk of cardiovascular death in adults with diabetes mellitus type 2 and cardiovascular disease
Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimers, and other neurodegenerative diseases
Retatrutide is not FDA-approved, is not commercially available, and legitimate access is limited to appropriate clinical-trial participation
If you are looking for licensed weight loss medication, there are treatments that could be suitable for you following a consultation